NCT05332093 (SpatialCL) is a clinical trial of skin biopsy in Cutaneous Leishmaniases, sponsored by Institute of Tropical Medicine, Belgium.

Who is sponsoring NCT05332093?

NCT05332093 is sponsored by Institute of Tropical Medicine, Belgium.

What drugs are being tested in NCT05332093?

Interventions in NCT05332093: skin biopsy, venous blood sample (plasma, PBMC, WB), venous blood sample (HLA), skin slit.

What condition does NCT05332093 study?

NCT05332093 studies Cutaneous Leishmaniases.

Is NCT05332093 still recruiting?

NCT05332093 is currently completed. Last updated 9 January 2025.

Last reviewed 2025-01-09 · How we verify

NCT05332093: SpatialCL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Spatial Analysis of Host-parasite Interactions in Cutaneous Leishmaniasis in Ethiopia

Completed Last updated 9 January 2025

What this trial tests

trial testing skin biopsy in Cutaneous Leishmaniases in 92 participants. Completed in 31 December 2024.

Timeline

21 March 2022

Primary endpoint
30 March 2024

31 December 2024

Quick facts

Lead sponsor	Institute of Tropical Medicine, Belgium
Status	Completed
Study type	OBSERVATIONAL
Enrollment	92
Start date	21 March 2022
Primary completion	30 March 2024
Estimated completion	31 December 2024
Sites	1 location across Ethiopia

Drugs / interventions tested

skin biopsy
venous blood sample (plasma, PBMC, WB)
venous blood sample (HLA)
skin slit

Conditions studied

Cutaneous Leishmaniases — all drugs for Cutaneous Leishmaniases →

Sponsor

Institute of Tropical Medicine, Belgium

Who can join

Adults 12 to 50, any sex, with Cutaneous Leishmaniases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cutaneous leishmaniasis manifestations range from self-healing localized skin ulcers/nodules to diffusely spread chronic lesions. Knowledge on the host-parasite interactions underpinning the different clinical presentations is scarce, in particular for L. aethiopica infections where disease can be extremely severe. Our aim is to define differences in skin immune responses and parasite virulence in CL patients at single cell/parasite level and how it underpins the different clinical presentations (localised, mucocutaneous and diffuse), by producing the first spatially-resolved 'ecological' map of the lesions.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Immunopeptidomics of cutaneous leishmaniasis patients reveals the natural antigenic landscape.
de Vrij N, Pepermans E, Laurijssen L, Pham TT, et al · · 2026 · PMID 41798914 · DOI 10.3389/fimmu.2026.1765843
From dogma to data: charting a path forward for clinico-immunological research in Ethiopian cutaneous leishmaniasis.
Pham TT, van Henten S, Woldetensay M, Asres MS, et al · · 2026 · PMID 41540511 · DOI 10.1186/s40249-025-01398-2

Verify or expand the search:

Other trials of skin biopsy

Trials testing the same drug.

NCT07075107 — Transcriptomic Analysis of Fibroblasts and Blood in Patients With Rare Diseases · NA · not yet recruiting
NCT06444217 — Gene Therapy Development and Validation for Huntington's Disease Fibro TG-HD · NA · recruiting
NCT06792487 — Immune Infiltrate Analysis of Psoriasis Skin During Therapy With Anti-interleukin 23 (IL-23) · recruiting
NCT06336473 — Evaluation of the Effects of Cross Linking on the Biomechanical Characteristics of Skin Samples From Patients With Class · NA · not yet recruiting
NCT06050330 — CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study · NA · completed

Other recruiting trials for Cutaneous Leishmaniases

Currently open trials in the same condition.

NCT06514560 — OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis Patients · recruiting

Other Institute of Tropical Medicine, Belgium trials

Trials by the same sponsor.

NCT07463040 — Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL) · Phase 3 · not yet recruiting
NCT07174648 — Testing of a New Rapid Antigen Test for Plague in Ituri, Democratic Republic of the Congo. · not yet recruiting
NCT07499739 — Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination (MBOTE-TRAXX) · Phase 4 · not yet recruiting
NCT07342829 — Prospective Follow-up After MVA-BN Booster Vaccination · not yet recruiting
NCT06839989 — An Immunogenicity and Safety Trial of MVA-BN in Adults Living With HIV for the Prevention of Mpox Infection, in Kinshasa · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05332093 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Tropical Medicine, Belgium
Last refreshed: 9 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05332093.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing